CVS Caremark nears settlement with FTC as federal regulators target insulin pricing practices

robot
Abstract generation in progress

CVS Caremark is nearing a settlement with the Federal Trade Commission (FTC) regarding its insulin pricing practices. The FTC had previously accused “Big 3 PBMs” of influencing drugmakers to increase prices through a “rebate-chasing” scheme. This potential settlement comes as federal regulators continue to scrutinize the operations of pharmacy benefit managers like CVS Caremark.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin